Hematology. American Society of Hematology. Education ProgramHumansLeukemiaMyeloidAcuteBridged Bicyclo Compounds
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?
William Nicol, Andrew H Wei
Published: 202510.1182/hematology.2025000756
Abstract
Combined hypomethylating agent (HMA) plus venetoclax (Ven) therapy enables most older patients with acute myeloid leukemia (AML) to achieve clinical remission. Key objectives are now aimed at developing new triplet combinations to circumvent mechanis…
Preview only. Read the full abstract at the source